Isolation and identification of tumor‑initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133

Yu,Jiwei; Tang,Zhaohui; Gong,Wei; Zhang,Mingdi; Quan,Zhiwei

doi:10.3892/ol.2017.7159

Isolation and identification of tumor‑initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133

Authors:
- Jiwei Yu
- Zhaohui Tang
- Wei Gong
- Mingdi Zhang
- Zhiwei Quan
View Affiliations

Affiliations: Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/ol.2017.7159
Pages: 7111-7120
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to isolate and identify the properties of the cluster of differentiation (CD)133+ subset in human gallbladder cancer cells. The CD133+ and CD133‑ subpopulations of the GBC‑SD cell line were separated using immunomagnetic separation, and the biological features of the two subpopulations were analyzed in vitro and in vivo. In particular, the present study aimed to determine whether the two subpopulations were resistant to anti‑tumor reagents and to identify the underlying molecular mechanisms involved. Following cell sorting of GBC‑SD cells using immunomagnetic beads, 90.2±2% of cells were identified as CD133+. Immunofluorescence confirmed that CD133 was expressed at higher levels in the Cd133+ group compared with the CD133‑ group. The proliferation of the CD133+ group was significantly increased compared with the CD133‑ group in vitro and in vivo. Following treatment with fluorouracil or gemcitabine, cells in the CD133+ group exhibited a decreased sensitivity to these drugs. The number of transmembrane cells was significantly increased in the CD133+ group compared with the CD133‑ group. In addition, the expression levels of ATP binding cassette subfamily G member 2, CD44, C‑X‑C motif chemokine receptor 4 (CXCR4), phosphorylated-protein kinase B (Akt) and CD133 in the CD133+ group were significantly increased, compared with those in the CD133‑ group. In CD133+ GBC‑SD cells, stromal cell‑derived factor 1α (SDF‑1α) or treatment with AMD3100, an inhibitor of CXCR4, promotes or suppresses the SDF‑1α/CXCR4 axis, respectively, resulting in increased or decreased CD133 expression through the Akt signaling pathway. Inhibition of the Akt signaling pathway resulted in decreased CD133 expression in GBC‑SD cells. Immunomagnetic beads were successfully used for isolation of the CD133+ subset from GBC‑SD cells. Furthermore, the CD133+ subset revealed an increased potential for tumor formation, cell proliferation, invasion and resistance to chemotherapeutic agents with expression of stem cell‑associated genes. Therefore, in GBC‑SD cells, the CXCR4/Akt/CD133 signaling pathways may be activated.

View Figures

View References

1	Park HS, Lim JY, Yoon DS, Park JS, Lee DK, Lee SJ, Choi HJ, Song SY, Lee WJ and Cho JY: Outcome of adjuvant therapy for gallbladder cancer. Oncology. 79:168–173. 2010. View Article : Google Scholar : PubMed/NCBI
2	Misra S, Chaturvedi A, Misra NC and Sharma ID: Carcinoma of the gallbladder. Lancet Oncol. 4:167–176. 2003. View Article : Google Scholar : PubMed/NCBI
3	Meacham CE and Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature. 501:328–337. 2013. View Article : Google Scholar : PubMed/NCBI
4	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
5	Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 104:pp. 10158–10163. 2007, View Article : Google Scholar : PubMed/NCBI
6	Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
7	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
8	Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I and Mor G: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 8:158–166. 2009. View Article : Google Scholar : PubMed/NCBI
9	Choy W, Nagasawa DT, Trang A, Thill K, Spasic M and Yang I: CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Neurosurg Clin N Am. 23:391–405. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lee HJ, You DD, Choi DW, Choi YS, Kim SJ, Won YS and Moon HJ: Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J Korean Surg Soc. 81:263–270. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wang C, Xie J, Guo J, Manning HC, Gore JC and Guo N: Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 28:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
12	Sugihara E and Saya H: Complexity of cancer stem cells. Int J Cancer. 132:1249–1259. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kreso A and Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell. 14:275–291. 2014. View Article : Google Scholar : PubMed/NCBI
14	Yin BB, Wu SJ, Zong HJ, Ma BJ and Cai D: Preliminary screening and identification of stem cell-like sphere clones in a gallbladder cancer cell line GBC-SD. J Zhejiang Univ Sci B. 12:256–263. 2011. View Article : Google Scholar : PubMed/NCBI
15	Shi CJ, Gao J, Wang M, Wang X, Tian R, Zhu F, Shen M and Qin RY: CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol. 17:2965–2971. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chatterjee S, Behnam Azad B and Nimmagadda S: The intricate role of CXCR4 in cancer. Adv Cancer Res. 124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
18	Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, et al: Akt activation and localization correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet. 41:161–170. 2004. View Article : Google Scholar : PubMed/NCBI
19	Friedl P and Alexander S: Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell. 147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yu JW, Zhang P, Wu JG, Wu SH, Li XQ, Wang ST, Lu RQ, Ni XC and Jiang BJ: Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res. 29:1412010. View Article : Google Scholar : PubMed/NCBI
21	Lu RQ, Wu JG, Zhou GC, Jiang HG, Yu JW and Jiang BJ: Sorting of CD133(+) subset cells in human gastric cancer and the identification of their tumor initiating cell-like properties. Zhonghua Wei Chang Wai Ke Za Zhi. 15:174–179. 2012.PubMed/NCBI
22	Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao X, et al: CD133(+)CXCR4(+) colon cancer cells exhibitmetastatic potential and predict poor prognosis of patients. BMC Med. 10:852012. View Article : Google Scholar : PubMed/NCBI
23	Magee JA, Piskounova E and Morrison SJ: Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell. 21:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
24	O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007. View Article : Google Scholar : PubMed/NCBI
25	Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM and Isaacs JT: The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 68:9703–9711. 2008. View Article : Google Scholar : PubMed/NCBI
26	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
27	Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW and Mahato RI: Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One. 7:e400212012. View Article : Google Scholar : PubMed/NCBI
28	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
29	Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
30	Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al: Induced pluripotent stem cell lines derived from human somatic cells. Science. 318:1917–1920. 2007. View Article : Google Scholar : PubMed/NCBI
31	Liu DC, Yang ZL and Jiang S: Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Cancer Biomark. 8:113–121. 2010–2011. View Article : Google Scholar
32	Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P and Sibilia M: Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 140:268–279. 2010. View Article : Google Scholar : PubMed/NCBI
33	Li CF, Fang FM, Wang JM, Tzeng CC, Tai HC, Wei YC, Li SH, Lee YT, Wang YH, Yu SC, et al: EGFR nuclear import in gallbladder carcinoma: Nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. Ann Surg Oncol. 19:443–454. 2012. View Article : Google Scholar : PubMed/NCBI
34	Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB and Cai MY: Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J Surg Oncol. 107:799–806. 2013. View Article : Google Scholar : PubMed/NCBI
35	Britton KM, Eyre R, Harvey IJ, Stemke-Hale K, Browell D, Lennard TW and Meeson AP: Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 323:97–105. 2012. View Article : Google Scholar : PubMed/NCBI
36	Ping YF, Yao XH, Jiang JY, Zhao LT, Yu SC, Jiang T, Lin MC, Chen JH, Wang B, Zhang R, et al: The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signaling. J Pathol. 224:344–354. 2011. View Article : Google Scholar : PubMed/NCBI